Finanzas de Astrana Health, Inc. (ASTH)ASTHAstrana Health, Inc.

Astrana Health, Inc. (ASTH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Medicare, accounting for 63.0% of total sales, equivalent to $608.12M. Other significant revenue streams include Medicaid and Commercial. Understanding this composition is critical for investors evaluating how ASTH navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Astrana Health, Inc. maintains a gross margin of 9.10%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 4.02%, while the net margin is 1.90%. These profitability ratios, combined with a Return on Equity (ROE) of 5.08%, provide a clear picture of how effectively ASTH converts its operational activities into shareholder value.

In the context of the broader market, ASTH competes directly with industry leaders such as NRC and DGX. With a market capitalization of $2.27B, it holds a significant position in the sector. When comparing efficiency, ASTH's gross margin of 9.10% stands against NRC's 56.41% and DGX's 32.53%. Such benchmarking helps identify whether Astrana Health, Inc. is trading at a premium or discount relative to its financial performance.

Astrana Health has demonstrated strong financial performance with a total revenue of $972.5 million in Q2 2026, reflecting a year-on-year growth of 48.5%. The company has also improved its adjusted EPS to $0.40, showcasing effective cost management.